# Sai Parenterals (NSE: SAIPARENT) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SAIPARENT · Pivot · prices to 22 Oct 2026

Sai Parenterals (NSE: SAIPARENT) closed at ₹461.90 on 22 Oct 2026, down 1.31% on the day. With a market capitalisation of ₹2,041 Cr, it ranks 1140th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 103.6× trailing earnings, against a return on equity of 2.9% in FY26. Its 52-week range is ₹400.00 (2 Apr 2026) to ₹706.00 (2 Jul 2026); the last close is 34.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹198 Cr and net profit ₹13 Cr, on a consolidated basis. Promoters held 51.16% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹461.90 |
| Market cap | ₹2,041 Cr |
| P/E (trailing) | 103.6 |
| ROE | 2.9% (FY26) |
| ROCE | 3.6% (FY26) |
| Debt to equity | 0.65 |
| 52-week high | ₹706.00 (2 Jul 2026) |
| 52-week low | ₹400.00 (2 Apr 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹198 Cr | — | ₹13 Cr | — | ₹4.02 |
| Q3 FY26 | ₹96 Cr | — | −₹7 Cr | — | −₹1.51 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹163 Cr | ₹14 Cr |
| FY24 | ₹154 Cr | ₹8 Cr |
| FY23 | ₹97 Cr | ₹4 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 51.16%
- Foreign institutions: 4.03%
- Domestic institutions: 8.53%
- Non-institutions: 36.29%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Syncom Formulations (India)](https://app.pivotnow.in/stock/SYNCOMF) | ₹22.83 | ₹2,146 Cr | 28.2 | — |
| [Indoco Remedies](https://app.pivotnow.in/stock/INDOCO) | ₹230.55 | ₹2,128 Cr | — | — |
| [Panacea Biotec](https://app.pivotnow.in/stock/PANACEABIO) | ₹335.85 | ₹2,057 Cr | — | — |
| [Sakar Healthcare](https://app.pivotnow.in/stock/SAKAR) | ₹923.90 | ₹2,056 Cr | 67.6 | — |
| [Beta Drugs](https://app.pivotnow.in/stock/BETA) | ₹1,773.00 | ₹1,966 Cr | 43.4 | — |
| [Hester Biosciences](https://app.pivotnow.in/stock/HESTERBIO) | ₹2,165.00 | ₹1,842 Cr | 32 | — |

## Questions and answers

### What is the share price of Sai Parenterals today?

Sai Parenterals (NSE: SAIPARENT) last closed at ₹461.90 on 22 Oct 2026. Its 52-week high is ₹706.00 and its 52-week low is ₹400.00.

### What is the market cap of Sai Parenterals?

Sai Parenterals' market capitalisation is ₹2,041 Cr (₹2,041 Cr) at the 22 Oct 2026 close, ranking 1140th among the NSE companies Pivot tracks.

### What is the P/E ratio of Sai Parenterals?

Sai Parenterals trades at a trailing P/E of 103.6. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 43.4.

### What is the ROE and ROCE of Sai Parenterals?

Return on equity was 2.9% in FY26 and return on capital employed was 3.6% in FY26 (consolidated figures).

### Is Sai Parenterals a debt-free company?

No. Sai Parenterals' debt-to-equity ratio was 0.65 in FY26, with total debt of ₹90 Cr.

### What were Sai Parenterals' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Sai Parenterals reported revenue of ₹198 Cr and net profit of ₹13 Cr.

### What is the shareholding pattern of Sai Parenterals?

As of 30 Jun 2026: promoters 51.16%, foreign institutions 4.03%, domestic institutions 8.53%, non-institutions 36.29%.

### Who are Sai Parenterals' competitors?

The listed Pharma & Healthcare companies closest to Sai Parenterals by market cap are Syncom Formulations (India), Indoco Remedies, Panacea Biotec, Sakar Healthcare, Beta Drugs and Hester Biosciences.

### Is Sai Parenterals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Sai Parenterals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAIPARENT against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.